PALB2 Linked to Increased Risk for Breast, Ovarian, and Pancreatic Cancer

January 8, 2020 10:00 am

By Christina Bennett, MS

Germline PALB2 pathogenic variants were associated with an increased risk for female breast cancer, male breast cancer, ovarian cancer, and pancreatic cancer, and these risks varied by age, according to data from an international study … Read more

Talc Powder Not Linked to Ovarian Cancer in Prospective Datasets

January 7, 2020 5:00 pm

By Ian Ingram

— With some 250,000 participants, study rules out all but smallest risk increases

New research on a quarter-million women from four U.S. cohorts found no significant association between ovarian cancer and the use of powder-based products in … Read more

Siravatinib/Tislelizumab Signals Efficacy in Patients With Platinum-Resistant Ovarian Cancer

December 19, 2019 6:00 pm

By Nichole Tucker

Preliminary data showed that the combination of sitravatinib (MGCD516) and tislelizumab (BGB-A317) is well tolerated and may promote antitumor activity when administered to patients with platinum-resistant ovarian cancer, according to a press release from BieGene, Ltd, which … Read more

Molecular Profiling As a Necessity for Uncommon Ovarian Cancers

November 5, 2015 11:00 am

By: Laura Shawver

In 1998, Herceptin was approved for women with breast cancer whose tumors have extra copies of the Her2/ERBB2 gene and since that time, there have been more than 25 drugs approved to treat cancers with specific genetic … Read more

Why Are Many Women At Risk of Ovarian Cancer Not Aware Of It?

November 2, 2015 11:00 am

The statistics for ovarian cancer are frightening. Whereas early detection tests for breast cancer are relatively commonplace, 75-85% of women with ovarian cancer are diagnosed only at a late stage, when the cancer has spread and prognosis is poor.

More … Read more

Effective Ovarian Cancer Treatment Is Underused, Study Finds

October 30, 2015 11:00 am

Deborah Denehy received chemotherapy directly to her abdomen to treat ovarian cancer, a treatment that remains underused in the United States. Credit Shiho Fukada for The New York Times.

In 2006, the National Cancer Institute took the rare step … Read more

Liz Laats Shares Her Story at Clearity’s Glitter and Glue for Good

October 27, 2015 11:00 am

Check out Liz Laats’ amazing speech at Glitter and Glue for Good, not a dry eye in the house.

Thank you to everyone who joined us on March 7th for the inaugaural Glitter & Glue for Good event. More than … Read more

Molecular Profiling of Epithelial Ovarian Cancer

October 24, 2015 11:00 am

Epithelial ovarian cancer (EOC) is the most common cause of gynecological cancer death in the United States, with an estimated 21,290 new cases and 14,180 deaths estimated for 2015 (ACS 2015). The vast majority of women are diagnosed with advanced … Read more

Heart Drug Linked to Extra Years for Cancer Patients

October 20, 2015 11:00 am

A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.

Researchers analyzing a database … Read more

A Heart to Heart Community for Ovarian Cancer Survivors

October 17, 2015 11:00 am

Welcome to my Heart to Heart blog designed in the Clearity Portal to provide ovarian cancer survivors with a “cozy space” where we know we will be welcomed and supported.

I’ve been an ovarian cancer survivor for 7 years. I’ve … Read more